{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "FlublokPI",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": "comp_1",
      "quote": "Flublok contains recombinant Ha proteins of the three strains of influenza virus specified by health authorities for inclusion in the annual seasonal vaccine. These proteins function as antigens which induce a humoral immune response, measured by hem agglutination inhibition (HI) anti bod",
      "reason": "does not support claim",
      "original_explanation": "This quote explains that Flublok (a recombinant flu vaccine) is designed to induce a humoral immune response, which is measured by antibody production, supporting the claim that it can induce a robust antibody response."
    },
    {
      "id": "comp_2",
      "quote": "For the 2024-2025 influenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 influenza virus strains...",
      "reason": "does not support claim",
      "original_explanation": "This quote provides evidence that Flublok is a higher-dose vaccine (135 mcg total HA), which is relevant to the claim that a higher-dose recombinant vaccine may induce a more robust antibody response compared to standard-dose vaccines."
    }
  ],
  "model_used": "gpt-4.1"
}